Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

5.060 -0.090 (-1.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
From Personalis, Inc.
Via Business Wire
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
From Personalis, Inc.
Via Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
From Personalis, Inc.
Via Business Wire
Personalis Reports First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
From Personalis, Inc.
Via Business Wire
Personalis to Announce First Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
From Personalis, Inc.
Via Business Wire
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
From Personalis, Inc.
Via Business Wire
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
From Personalis, Inc.
Via Business Wire
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
From Personalis, Inc.
Via Business Wire
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
From Personalis, Inc.
Via Business Wire
Personalis and Tempus Expand Collaboration to Biopharma
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis Reports Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Present at the Stifel 2024 Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis to Announce Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
From Personalis, Inc.
Via Business Wire
Biotech Stock Soars 60% in 2024: Cathie Wood’s Bold Investment
Tempus AI is a hot healthcare stock that investors should be aware of. It is using AI to pursue "precision medicine", especially in cancer research. 
Via MarketBeat
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis and Tempus Announce Expanded Collaboration
From Personalis, Inc.
Via Business Wire
Personalis Reports Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.